New vaccine aims to shield against multiple coronaviruses at once

NCT ID NCT05548439

Completed ⭐️ VACCINE ⭐️ Sponsor: VBI Vaccines Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental vaccine called VBI-2901a in 103 healthy adults aged 18-64 who had already received at least two doses of a licensed COVID-19 vaccine. The vaccine is designed to protect against three coronaviruses: SARS-CoV-2 (which causes COVID-19), SARS-CoV-1, and MERS-CoV. The main goals were to check safety and see how well the vaccine boosts the immune system's response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONAVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease Coronaviridae infectious disease Orthocoronavirinae infectious disease severe acute respiratory syndrome COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONAVIRUS INFECTIONS COVID-19

Contacts and locations

Locations

CHU de Québec Université Laval

Québec, Quebec, G1E 7G9, Canada
Canadian Center for Vaccinology

Halifax, Nova Scotia, B3K 6R8, Canada
LMC Manna - Bayview CPU

Toronto, Ontario, M4G 3E8, Canada
LMC Manna Toronto

Toronto, Ontario, M9W 4L6, Canada
Manna Research Inc

Pointe-Claire, Quebec, H9R 4S3, Canada
Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
Red Maple Trials

Ottawa, Ontario, K1H 1E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.